Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

July 28, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

January 15, 2019

Conditions
Cervical Cancer
Interventions
DRUG

Bevacizumab

Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks

DRUG

Carboplatin

Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles

DRUG

Paclitaxel

Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles

Trial Locations (43)

1330

MHAT Nadezhda, Sofia

2013

Wits Clinical Research, Johannesberg

4004

Complex Oncological Center - Plovdiv, EOOD, Plovdiv

10103

Clinica CIMCA, San José

11000

Institute for Onc/Rad Serbia, Belgrade

14076

Centre Francois Baclesse; Urologie Gynecologie, Caen

14080

Instituto Nacional de Cancerologia; Oncology, Distrito Federal

15706

Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela

20133

Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, Milan

20141

Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milan

28033

Centro Oncologico MD Anderson International Espana, Madrid

28046

Hospital Universitario La Paz; Servicio de Oncologia, Madrid

34390

Istanbul Uni of Medicine Faculty; Oncology Dept, Istanbul

46009

Instituto Valenciano Oncologia; Oncologia Medica, Valencia

46026

Hospital Universitario la Fe; Servicio de Oncologia, Valencia

50180

Centro Oncologico Estatal ISSEMYM, Toluca

80131

Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica, Napoli

94800

Institut Gustave Roussy; Oncologie Medicale, Villejuif

115280

Alexandras General Hospital of Athens; Oncology Department, Athens

115478

Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy, Moscow

197022

St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint Petersburg

200347

Centrul de Oncologie Sfantul Nectarie, Craiova

230002

Oncomedica S.A., Montería

600004

Oncólogos de Occidente, Pereira

700483

Regional Institute of Oncology Iasi, Iași

F5300COE

Centro Oncologico Riojano Integral (CORI), La Rioja

31270-901

Hospital das Clinicas - UFMG, Belo Horizonte

66053-000

Oncologica Brasil S/S LTDA - EPP, Belém

20560-120

Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janerio

01246-000

Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo

151 23

IASO, Athens

00168

Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica, Rome

03100

Consultorio de Medicina Especializada, México

0801

Centro Oncológico de Panamá, Panama City

0832

Centro Hemato Oncologico Panama, Panama City

15-027

Bialostockie Centrum Onkologi, Bialystok

31-115

Centrum Onkologii Instytut im. M.Sklodowskiej-Curie; Klinika Ginekologii Onkologicznej, Krakow

61-866

Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie, Poznan

02-781

Centrum Onkologii - Instytut M.Sklodowskiej-Curie; Klinika Ginekologii Onkologicznej, Warsaw

4200-072

IPO do Porto; Servico de Oncologia Medica, Porto

0002

University of Pretoria; Department of Medical Oncology, Pretoria

08907

Hospital Duran i Reynals; Oncologia, Barcelona

06500

Ankara Baskent University Medicine Faculty; Gynaecology, Ankara

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02467907 - Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | Biotech Hunter | Biotech Hunter